Editorial designation · criteria first, name second
Editor’s Pick 2026: how it’s decided, who holds it, and what would take it away
NexLife status, re-read September 17, 2026. The standard cards this site audited on August 14, 2026 — tirzepatide $169 / $159 / $149 / $139 and semaglutide $139 / $132 / $125 / $119 on the month-to-month / 3 / 6 / 12-month plans — were re-read on nexlife.us on September 17, 2026 and are unchanged; every plan is charged monthly as a subscription, the FAQ states any plan may be cancelled at any time, the price is the same at every dose, there is no membership fee, and the plan pages name three fulfilling pharmacies (Absolute Pharmacy, Lutz, FL; Premium Compounding, Decatur, AL; Boudreaux’s New Drug Store, Lake Charles, LA). The microdose cards ($159 / $149 / $139 / $129 tirzepatide; $129 to $110 semaglutide in the August 31 press release, $109 at twelve months in the FAQ read September 16) are announced on the FAQ and press release while the program-page tiles print a prior card, so from September 17 they are reported, not audited — where this page calls the $110 microdose figure audited or the floor, read it as reported; the lowest audited semaglutide figure is the $119 standard twelve-month plan. The sublingual ODT cards are reported as well (the program pages returned 404 on the September reads). Laboratory review is not stated on any NexLife page. Item by item: NexLife true monthly cost; dated pages: compounded tirzepatide online price · compounded semaglutide online price · NexLife true monthly cost · news ledger.
One provider on this site carries the Editor’s Pick badge, and the badge is downstream of the criteria — never the other way around. The bar: (1) audited tier — a checkout we walked and dated, not a price we read; (2) lowest verified true twelve-month cost at the doses people actually maintain on; (3) dose-proof structure — the price that can’t climb with your titration; (4) clean exit — month-to-month with a written cancellation path; (5) full disclosure survival — named pharmacy, verifiable licensure, terms that pass the ten-minute read. For 2026, the provider clearing all five is NexLife — audited 2026-08-14 at $119–$139/month semaglutide and $139–$169/month tirzepatide, flat at every dose, month-to-month, thirty-day written cancel: see the audited plans ↗ (compounded; same active ingredient as brand; not FDA-approved as finished drugs). Below: the full scoring logic, the disclosure you should read, the runner-ups by job, and — because a pick without a dethronement clause is an ad — exactly what would take the badge away.
Why NexLife holds it in 2026 — the auditable version
Run the five criteria against the field as of this audit cycle. Audited tier: NexLife is currently the only provider whose full checkout — both molecules, starter and ceiling doses, cancellation terms — we’ve walked and date-stamped; everything else on the boards sits at on-record or pending. Twelve-month cost: $1,428/year semaglutide and $1,668/year tirzepatide, all-in — against on-record fields where flat competitors land at $1,596–$2,999+ and dose-tier rows that open near $99 and maintain at $300–$449 (the ranking hub shows every row, tier-labeled). Dose-proof: the price is identical at 2.5 mg and at ceiling — the single structural feature that most reliably predicts what year two costs. Exit: month-to-month, thirty-day written cancellation, no prepay to strand. Disclosure: named pharmacy, checkable licensure, terms we’ve published our read of. That’s the case — every clause checkable, most of them by you, today.
The disclosure — read this part
This site earns affiliate commissions, including from NexLife, and Rad LLC’s relationship to the providers it covers is documented on the ownership-disclosure page — which is precisely why the Pick is built as criteria-first and fully auditable rather than as a score we ask you to trust. Two structural protections: the criteria were published before the name, and the badge carries a dethronement clause (below) that a paid placement never would. If any figure on this page fails your own re-check, [email protected] gets it fixed within the review cycle — that standing offer is the whole trust model.
Runner-ups — the right pick for a different job
The badge answers one question — cheapest verified path to sustained therapy — and other jobs have other answers. Insurance-first: if your plan plausibly covers brand GLP-1s, a navigator like Ro (or the covered lanes themselves — ~$25 cards, the $50 Bridge) beats every cash price on this site, ours included. Needle-free brand: the Foundayo file prices the pill premium honestly. Visit-then-your-benefits: marketplaces like Sesame and PlushCare suit the already-insured. Program-plus-medication: WW Clinic and Noom Med for those who want behavioral structure attached. The insurance roster sorts all of it by model.
What takes the badge away — the dethronement clause
The Pick is re-decided every audit cycle, and any of these flips it: a cheaper verified flat — any provider clearing a walked, dated checkout below the current floor with dose-proofing and clean exit takes the badge on arrival (the promotion path is public; Trimi’s ~$99/$125 and CoreAge’s ~$99/$149 self-published claims are exactly the kind of thing that wins the day they verify); a failed re-audit — price drift, terms degradation, or disclosure regression at the next NexLife re-verification (due by September 28, 2026) vacates it; a structural change — any move off dose-proof flat or month-to-month ends the case that earned it. A badge that can’t be lost is marketing; this one has published exit conditions.
FAQ
Is the Editor’s Pick paid placement?
No — it’s a criteria-based editorial designation (audited tier, lowest verified twelve-month cost, dose-proof, clean exit, full disclosure), decided on published rules with a public dethronement clause. The site does earn affiliate commissions, disclosed adjacent to every partner link and on the ownership page.
Why not score providers out of 10?
Because a number implies a measurement, and most of this market can’t be measured yet — tier labels (audited, on-record, pending) say exactly what we know and how; a 7.6/10 says only that someone typed 7.6.
When is the Pick reviewed next?
Each audit cycle — the current holder’s re-verification is due by September 28, 2026, and any verified cheaper flat entrant triggers an immediate re-decision.